Robotic-assisted surgery is the most commercially significant technology transition in orthopedics in a generation. Stryker's Mako platform — with over 1,800 installed systems globally — has established the commercial template: capital equipment placement drives implant pull-through, increases procedure volume, and creates switching costs that defend market share against price competition. Every major orthopedic OEM is now competing to establish a comparable robotics installed base.

Zimmer Biomet's ROSA has reached over 1,200 installations. Globus Medical's ExcelsiusGPS leads in spine robotics with over 800 systems and is expanding into hip arthroplasty. DePuy Synthes's Velys has reached over 500 installations. Smith & Nephew's CORI is growing. The competitive dynamics of the robotics installed base race will determine market share in joint reconstruction and spine for the next decade.

This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.


Topics Covered
• Robotics Installed Base Analysis
• Mako Commercial Model and Pull-Through Economics
• ROSA, ExcelsiusGPS, Velys, CORI Competitive Analysis
• Capital Sales Strategy
• Robotics Reimbursement
• Next-Generation Robotics Development